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Effect of glyoxylate on the function of the catcitriol receptor and vitamin
D metabolism. The biological action of calcitriol is mostly mediated
through the interaction of the calcitriol receptor (VDR) with vitamin D
response elements (VDREs) of target genes. These interactions produce
special proteins that carry out the biological activities of calcitriol.
Recently, we showed that the interaction of VDRs with VDREs is
inhibited by uremic toxins. We hypothesize that uremic toxins that contain
aldehyde or ketone groups potentially could form Schifi' bases with lysine
residues of the VDR DNA binding domain and inhibit VDR interaction
with VDREs. We therefore chose glyoxylate, a compound which has an
aldehyde group, to test this hypothesis. In vitro glyoxylate inhibited VDR
binding to the osteocalcin and osteopontin VDREs as assessed by
electrophoretic mobility shift assay and the inhibition was reversed when
glyoxylate was preincubated with lysine. Further, this chemical compound
also blocked the induction of chioramphenicol acetyltransferase (CAT)
enzyme induced by calcitriol in cells transfected with a calcitriol responsive
CAT reporter gene. Since induction of 24-hydroxylase synthesis is a VDR
regulated process, we also studied the effect of glyoxylate on the activity of
intestinal 24-hydroxylase in rats. This enzyme activity was suppressed in
rats infused with glyoxylate. Taken together, our study suggests that
glyoxylate could inhibit the interaction of VDR with VDREs and alter the
biological action of calcitriol.
The biological actions of calcitriol are mostly receptor-medi-
ated processes. The hormone-receptor complexes interact with
vitamin D response elements (VDREs) and thus regulate the
transcription of genes. Therefore, inhibition of hormone-receptor
complex binding to VDREs will impair the transcription of target
genes. The interaction of VDRs with VDREs is inhibited by
uremic toxins [1]. This inhibition could account for the end-organ
resistance to calcitriol in renal failure [2, 3]. The mechanism of
inhibition by uremic toxins is unknown. Since it has been pro-
posed that pyridoxal 5'-phosphate forms Schiff bases with steroid
receptors and inhibits the receptor's interaction with DNA [4—7],
we propose that compounds with reactive aldehydes or ketones in
uremic plasma block VDR-VDRE interactions by an analogous
Schiff base mechanism. Thus, chemicals capable of Schiff base
formation with VDR potentially could alter the physiological
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function of VDR and calcitriol metabolism. In search of uremic
toxins that potentially could influence the function of VDR and
thereby alter calcitriol metabolism, we identified glyoxylate as a
compound that has an aldehyde moiety. Glyoxylate is a precursor
of oxalate. Although its concentration has not been measured in
renal failure, plasma oxalate is elevated in end-stage renal failure
[8, 9]. Plasma glyoxylate, however, is elevated in hyperoxaluria
[10]. In this study, we examined the effects of glyoxylate on VDR
binding to a VDRE in vitro and on the transcription of a reporter
gene in cell culture using transiently transfected JEG-3 cells. In
addition, we studied the effect of glyoxylate on the synthesis of
intestinal 24-hydroxylase, a receptor regulated process, in animals
[11, 12].
METHODS
Electrophoretic mobility shift assay (EMSA) of intestinal VDR
or recombinant VDR incubated with glyoxylate
Intestinal VDR binding to the osteocalcin VDRE: Preparation of
intestinal VDR. Rats were decapitated and the initial 20 cm of
small intestine distal to the pylorus (duodenum and portion of
jejunum) was removed and flushed with ice-cold Ca/Mg-free
phosphate (6.6 mst Na2HPO4, 250 lU/mI Trasylol and 1.5 mM
KH2PO4)-buffered saline (CMF-PBS). The mucosal cells were
scraped from the serosa, washed three times in 20 volumes of
CMF-PBS and centrifuged at 200 X g for five minutes after each
washing. The tissue was homogenized by a Polytron in 20 vol
(wt/vol) of buffer consisting of 200 ig/ml soybean trypsin inhibi-
tor, 10 mM Tris-HC1 (pH 7.4), 1 msn EDTA, 10 m sodium
molybdate, 5 ms't dithiothreitol (TED) and 300 mivt KC1 (KTED)
[13]. Cellular protein was prepared by centrifugation at 100,000 X
g for 45 minutes at 0 to 4°C.
Electrophoretic mobility shift assay (EMSA). A 36-base pair
synthetic oligonucleotide encompassing the rat osteocalcin gene
VDRE (base pairs —459 to —432 with CTAG overhangs [141) was
labeled by a fill-in reaction using the Kienow fragment of DNA
polymerase I and [cr-32P]dCTP. The labeled DNA probe was
purified on a Sephadex G-50 column.
Intestinal cellular proteins (15 1.d or approximately 40 .rg
cellular protein) were incubated for one hour with various con-
centrations of glyoxylate or oxalate (controls) (0, 1, 2.5 and 5.0 mM
in TED buffer, pH 7.4). Thereafter, the proteins were incubated
for another 15 minutes in 35 1.d of mobility shift reaction buffer
containing 5 m Tris, 15 mrvt Hepes, 3.5 m'i MgCl2, 5 mivi EDTA,
10% glycerol, 0.1% Tween 20, 5 mst dithiothreitol, 0.15 jg
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poly(dI-dC), and 100 mrvi KCI, pH 7.9 [15]. At the end of this
incubation, approximately 15,000 to 30,000 cpm of radiolabeled
osteocalcin VDRE probe was added in each mobility shift reac-
tion mixture. The reaction mixtures were gently vortexed, incu-
bated for another 10 minutes and electrophoresed on 4% nonde-
naturing polyacrylamide gels at 100 V for approximately three
hours. The mobility shift running buffer contained 50 mi Tris, 380
mM glycine, and 2 mivi EDTA (pH 8.5) [1, 16]. The dried gel was
autoradiographed, and the free and VDR-bound VDREs were
quantified by excising the appropriate portions of the gel followed
by liquid scintillation counting [1].
Recombinant human VDR binding to the osteopontin VDRE:
Preparation of recombinant human VDR. Full length recombinant
human VDR and mouse retinoid X receptor a (RXRa) proteins
were expressed from the vector pMalc2 (New England Biolabs).
This vector produces a fusion protein of maltose binding protein
followed by a cleavage site for factor Xa and the recombinant
protein. The fusion proteins of VDR and RXRa were purified by
affinity chromatography on an amylose column and cleaved with
factor Xa as previously described [1].
SchJf base reaction of glyoxylate and lysine. To test if pre-
formation of a Schiff base between glyoxylate and lysine may
prevent the inhibitory effect of glyoxylate on VDR binding to the
osteocalcin VDRE, we incubated 5 mrvi glyoxylate with 40 mM
L-lysine (pH 7.4) at 37°C for 10 and 28 days [17]. The mixtures
were then incubated with 250 ng of recombinant VDR and 100 ng
of RXRa for electrophoretic mobility shift assay (6% nondena-
turing polyacrylamide gel).
Recombinant truncated VDR binding to the osteopontin VDRE:
Preparation of a truncated VDR. We produced a truncated VDR
(amino acids ito 119) that lacks the ligand binding domain. The
PCR-based splicing by overlap extension technique was used to
place a stop codon after amino acid 119 with a standard protocol
and expressed in the E. coli expression plasmid vector pMalc2 as
described above. The fusion proteins of VDR were purified by
affinity chromatography [18]. The truncated VDR includes the full
zinc fingers and T and A box domains, but lacks the ligand binding
domain.
A 32 bp synthetic oligonucleotide encompassing the rat Os-
teopontin gene VDRE (bp —761 to —738 plus GATC overhangs
[19]) was labeled by a fill-in reaction and used as a probe. EMSA
incubations utilized approximately 250 ng of recombinant human
VDR or 10 ag of the truncated VDR. Receptors were incubated
individually for one hour at 15°C with 0 or 5 mi glyoxylate.
Thereafter, these receptor preparations were added to EMSA
incubations as described above.
Effect of glyoxylate on calcitriol-dependent expression of a
reporter gene in transfected JEG-3 cells
We used transiently transfected JEG-3 cells to study the effect
of glyoxylate on calcitriol induction of a reporter gene [1]. The
human VDR eDNA was expressed from the vector pCDM. The
reporter plasmid was derived from pUTKAT3 [19], and contained
two copies of the sequence 5'-GATCCACTAGGTCAAGGAG-
GTCATGGATC ligated 5' to the basal thymidine kinase pro-
moter (pTKD2AA) driving expression of chloramphenicol acetyl-
transferase (CAT). An internal control plasmid expressing human
growth hormone (hGH) from the basal thymidine kinase pro-
moter (pTKGL-l) was utilized to control for transfection efficiency.
Transfections included 4 jxg of pTKD2AA, 10 ng of pCDMVDR,
I jxg of pTKGH, and 6 jig of pCDM as filler plasmid per 60 mm
Petri dish. Cells were cultured 100 nM calcitriol and 2 mM
glyoxylate for 48 hours following transfection. Cell lysates were
analyzed for CAT activity and media for hGH as described [20].
The fold CAT induction is defined as CAT/hGH for cells cultured
with calcitriol divided by CAT/hGH for cells cultured without
calcitriol.
Intestinal 24-hydroxylase activity in normal rats infused with
glyoxylate
Normal Sprague-Dawley rats (200 to 220 g) fed with regular
Purina rat chow containing 1.0% Ca, 0.8% P, and 4.5 IU per g
vitamin D were used throughout the study. On the day of
experimentation, rats were weighed and anesthetized with ether.
The femoral artery and vein were cannulated with polyethylene
tubing (PE) for blood sampling and fluid infusion. A PE 50 tube
was inserted into the bladder for urine collection. The animals
were placed in individual cages and infused intravenously for 24
hours with 170 mg/100 g body wt of monosodium glyoxylate
dissolved in 50 to 60 ml normal saline solution (N =3). Control
animals (N = 4) were infused with 50 to 60 ml normal saline. At
the end of the infusion, arterial blood was withdrawn for mea-
surements of plasma concentration of creatinine and calcitriol.
Animals were killed and intestinal 24-hydroxylase activity was
measured 24 hours after the infusion.
Analytical methods
Creatinine was measured as described previously [21]. Plasma
calcitriol was measured in duplicate according to the methods of
Reinhardt et al [22] and Hollis [23]. Our interassay coefficients of
variation were 7.0% for low control (20 pg/mi, N = 12) and 4.1%
for high control (100 pg/mI, N = 12). The intraassay coefficients of
variation were 5.4% for low control (N = 6) and 4.7% for high
control (N = 6), respectively. Calcitriol recovery averaged 65%.
Intestinal 24-hydroxylase activity [assessed by conversion of
calcitriol to 1,24,25(OH)3D3] was measured according to previ-
ously described methods [24] with modification [25]. The intesti-
nal mucosa was scraped and homogenized in ice-cold 0.25 M
sucrose solution to yield a 2% wt/vol homogenate. One ml of the
homogenate was placed in a 25 ml Erlenmeyer flask. To each of
the flasks we added 0.5 ml of Buffer I (22 mivi glucose-6-
phosphate, 20 mt ATP disodium salt, 160 mrvi nicotinamide, 0.42
mM NAD, 0.37 mM NADP, 7.5 mM succinate, 0.1 M K2HPO4, pH
7.4) and 0.5 ml of Buffer II (5 mM MgC12, 0.1 M KCI, 0.2 U/mI
glucose-6-phosphate dehydrogenase, 0.85 U/mI alcohol dehydro-
gcnase). Vitamin D binding protein of the homogenates was
saturated with 50 jiM vitamin D3, so that calcitriol added to the
medium remained free from protein binding [26]. The mixture,
open to the atmosphere, was incubated and agitated (100 cycles/
mm) at 37°C. The reactions were terminated after two minutes of
incubation with the substrates by the addition of 10 ml methanol:
chloroform (2:1). 24-Hydroxylase activity was expressed as the
total generation of 1,24,25(OH)3D3 pmol per mg of intestinal
mucosa in two minutes. Five micrograms of cold 1,24,25(OH)3D3
was added to each flask for subsequent recovery measurements
during the extraction of the trihydroxyvitamin D metabolite.
The extraction of radiolabeled 1,24,25(OH)1D3 from incuba-
tion medium was identical to that described previously [25, 27].
Briefly, the reaction was terminated by the addition of methanol:
chloroform and the flask contents were decanted into 50 ml
S.
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Fig. 1. Inhibition of intestinal VDR-osteocalcin
VDRE complex by glyoxylate. Intestinal VDRs
were incubated for one hour with 1, 2.5, and 5
mM oxalate or glyoxylate and then incubated
with radiolabeled VDRE. Lane 1, incubation of
VDR with labeled VDRE to demonstrate the
VDR VDRE complex (arrow); addition of 100-
fold non-radiolabeled VDRE (lane 2) or 5 mM
pyridoxal 5'-phosphate (lane 3) to the mixtures
abolished the VDR-VDRE complexes; lane 4
to 6, addition of oxalate to the mixtures did not
inhibit VDR binding to the VDRE; lanes 7 to
9, addition of glyoxylate to the mixtures
inhibited VDR binding to the VDRE in a dose
dependent manner.
separatory tubes. Three milliters of homogenizing buffer and 4 ml
of chloroform were added to each tube. The mixture was vigor-
ously vortexed for 20 seconds and centrifuged at 200 g for 15
minutes. The upper aqueous phase was removed and the lower
organic phase containing lipids was aspirated and placed into 15
ml tubes. The chloroform was evaporated with nitrogen gas. The
pellet was reconstituted in one ml hexane:methanol:chloroform
(9:1:1) and applied to a Sephadex LH 20 column (0.6 cm X 15.5
cm). The column was washed with 18.0 ml of hexane:methanol:
chloroform (9:1:1) and the eluate was discarded. The column was
then washed with 11.0 ml of hexane:methanol:chloroform (8:2:2).
The eluate was collected into a 15 ml tube. The hexane:methanol:
chloroform was evaporated under nitrogen gas. The extract was
reconstituted in 0.5 ml 86:14 hexane:isopropanol and injected into
a Zorbax Sil silicic acid Dupont Column developed in 86:14
hexane:isopropanol. The tritiated trihydroxyvitamin D metaholite
was isolated using HPLC, mixed with organic phase scintillation
liquid and counted. The trihydroxyvitamin D metaholite was
quantitated by multiplying the ratio of tritiated trihydroxyvitamin
D metabolite to tritiated calcitriol with the amount of non-
radiolabeled calcitriol added to the reaction mixture.
RESULTS
Electrophoretic mobility shift assay (EMSA) of intestinal and
recombinant VDR incubated with glyoxylate
The effect of glyoxylate on the VDR-VDRE interaction is
depicted in Figure 1. Glyoxylate inhibited the interaction of VDR
with osteocalcin VDRE in a dose related manner. Oxalate even at
high concentration (5 mM) had no influence on VDR binding to
osteocalcin VDRE [103 11.4% compared to controls (0 mM),
N = 41, while 2.5 and 5 mrvt glyoxylate significantly reduced the
VDRs binding to the VDREs (2.5 mi, 74.5 4.3% and 5 mM,
31.4 4.1%, respectively. Both N = 4 and P < 0.01). Glyoxylate
also inhibited VDR binding to the osteopontin VDRE. However,
when glyoxylate was preincubated with lysine for 10 (not shown)
or 28 days, it no longer inhibited recombinant VDR binding to
osteopontin VDRE (Fig. 2).
The truncated VDR (119 amino acids) that contains the DNA
binding domain but not the ligand binding domain also demon-
strated decreased binding to the osteopontin VDRE when it was
pre-incubated with 5 mM glyoxylate for one hour (Fig. 3). Since
the truncated VDR only contains the short (23 amino acid) amino
terminal domain plus the DNA binding domain, the result
strongly suggests that glyoxylate interacts with the VDR DNA
binding domain, not the ligand binding domain (or at least that
interaction with the ligand binding domain is not necessary).
Effect of giyoxylate on the calcitriol-dependent expression of a
reporter gene in transfected JEG-3 cells
JEG-3 cells were transiently transfected with a VDR expression
plasmid, a VDRE-containing CAT reporter plasmid, and an
internal control plasmid expressing human OH. In the absence of
transfected VDR, calcitriol did not induce CAT (average 0.99-
fold, N = 4). Following cotransfection with the expression vector
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Fig. 2. Inhibitory effect of glyoxylate on VDR-
RXR-osteopontin VDRE complex formation is
reversed by L.Iysine. Lane 1, free radiolabeled
osteopontin VDRE; lane 2, Recombinant
VDR-RXR-VDRE complex (arrow); lane 3 and
4, addition of fresh or 28-day-old lysine did not
affect the VDR-RXR-VDRE complex; lane 5
and 6, addition of fresh or 28-day-old glyoxylate
inhibited the VDR-VDRE complexes; lane 7,
addition of 5 mi glyoxytate preincubated with
40 mM L-lysine at 37°C for 28 days failed to
inhibit VDR binding to VDRE.
pCDMVDR, calcitriol induced CAT activity 11.6-fold (Fig. 4,
control bar). Addition of glyoxylate specifically inhibited 43% of
calcitriol-induced CAT activity after normalization to hGH secre-
tion (6.7-fold; Fig. 4). Furthermore, this effect of glyoxylate was on
the calcitriol-induced activity, not the basal CAT activity (the
basal CAT activity; control, 27.7 I .4%Ing hGH vs. glyoxylate,
23.8 1.9%!ng hGH conversion, P = NS). Glyoxylate appeared
to suppress hGH secretion, though it did not reach statistical
significance (control, 1.02 0.37 ng/mg protein vs. glyoxylate,
0.40 0.12 ng/mg, P = NS). However, glyoxylate inhibited the
proliferation of JEG-3 cells by visual inspection. This observation
is supported by the finding of lower protein concentrations in
cultures containing glyoxylate (controls, 8.8 0.16 mg/mi vs.
glyoxylate, 4.9 0.14 mg/mI, P < 0.001).
Intestinal 24-hydroxylase activity in normal rats infused with
glyoxylate
Infusion of glyoxylate significantly suppressed 24-hydroxylase
activity in normal rats compared to the controls infused with
saline (Table 1). Plasma calcitriol levels increased following
glyoxylate infusion probably due to suppression of 24-hydroxylase
activity, though it may also suppress other degradation enzymes.
Plasma creatinine was increased in glyoxylate infused animals.
DISCUSSION
Most of the biological actions of calcitriol are mediated through
the interaction of the calcitriol receptors (VDR) with vitamin D
response elements (VDREs) of target genes. This interaction
results in production of proteins that carry out the biological
activity of calcitriol [28]. However, the biological activity of
calcitriol is decreased in renal failure [2, 3], and one of the reasons
perhaps is that uremic plasma contains factors that inhibit the
interaction of hormone-receptor complex with VDRE within cells
[1].
Although the chemical structures of the uremic toxins remain
unknown, we speculate that chemicals with reactive aldehyde or
ketone groups could form Schiff bases with lysine residues of the
VDR DNA binding domain thereby reducing VDR binding
affinity for VDRE. This supposition is based on the following
reasons. (1) The DNA binding domain is sensitive to chemical
modification [29], and a point mutation in the portion of the VDR
gene coding this domain impairs the VDR function [30, 31]. (2)
Pyridoxal 5'-phosphate has a reactive aldehyde group and is
capable of forming a Schiff base with steroid receptors and
reducing steroid receptor-DNA binding [4—7]. (3) Uremic plasma
contains chemical compounds with reactive aldehydes or ketones
[32].
Steroid receptor superfamily members share structural homol-
ogy in their DNA binding domains. These receptors have three
major regions (I to III) of conserved amino acids [28]. Region I
includes the DNA binding domain and contains a sequence of 66
highly conserved amino acids. Regions II and III are located
within the C-terminal or hormone binding domain of the receptor.
The DNA binding domain has two zinc fingers that contain eight
conserved cysteine residues and two zinc molecules. The VDR
DNA binding domain has 7 lysine residues, 3 of which are highly
conserved [33]. The formation of a Schiff base at these lysines
could inhibit VDR binding to VDRE. We hypothesize that
P<o.oo1
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glyoxylate, which has an aldehyde group, could also form Schiff
bases with lysine residues in the VDR DNA binding domain and
impair its binding to VDREs.
In this study, we have demonstrated that in vitro glyoxylate
inhibited VDR binding to the osteocalein VDRE in a dose
dependent manner. Further, when glyoxylate was pre-incubated
with lysine, glyoxylate had no inhibition in VDR binding to
osteopon tin VDRE. This is consistent with the expectation that by
reacting with free lysine, the glyoxylate aldehyde group would no
longer be available to form a Schiff base with lysine residues in the
VDR DNA binding domain. Using a truncated VDR, we have
shown that glyoxylate inhibited VDR binding to the osteopontin
VDRE. Since the truncated VDR lacks the hormone binding
domain, inhibition of the VDR-DNA interaction most likely
results from glyoxylate modification of the DNA binding domain.
If glyoxylate could chemically modify the VDR in vitro, it might
also alter the VDR in vivo. To test this hypothesis, we employed




Fig. 4. Effect of glyoxylate on calcitriol-induced expression of CAT activ-
ity in transfected JEG-3 cells. JEG-3 cells were transfected with a VDR
expression vector, a CAT reporter plasmid driven by a calcitriol responsive
promoter, and a human GH-expressing reporter as an internal control.
Cells were incubated with 0 (control) and 2.0 m'vi (experimental) glyoxy-
late, in each case with or without 100 nM calcitriol, for 48 hours. Fold CAT
induction is defined as CAT/human GH for cells cultured with calcitriol
divided by CAT/human GH for cell cultured without calcitriol. Results are











Saline infusion (N = 4) 0.48 0.03 70.6 6.0 4.30 0.08
Glyoxylate infusion (N = 3) 0.83 0.02 134.2 3.3 2.78 0.11
P value 0.001 0.001 0.001
24-Hydroxylase activity was determined by measuring the conversion
of 1,25(OH)2D3 to l,24,25(OH)3D3. Intestinal mucosa was incubated with
1,25(OH)2D3 for 2 mm.
calcitriol. We showed that glyoxylate impairs the ability of calci-
trio! to induce the expression of a target gene. However, it did not
suppress the basal activity of CAT expression by the cells. This
result is consistent with the hypothesis that glyoxylate could
interact with the VDR to impair its DNA binding within cells. It
should be noted that glyoxylate modestly inhibited the prolifera-
tion of JEG-3 cells during the 48 hours of incubation. However, by
normalizing CAT expression to hGH, which is driven by the same
basal promoter but without a VDRE, we were able to control for
any nonspecific effects on transcription.
Synthesis of 24-hydroxylase requires an interaction of the VDR
with a specific VDRE [34, 35]; therefore, inhibition of the VDR
binding to the VDRE of the 24-hydroxylase gene will result in
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Fig. 3. Inhibition of truncated VDR (VDR DNA binding domain) binding
to radiolabeled osteopontin YDRE by glyoxylate.
Table 1. Effect of glyoxylate infusion on plasma calcitriol, creatinine
and intestinal 24-hydroxylase activity
1 2 3
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rats and examined its effect on the activity of 24-hydroxylase. We
found that glyoxylate indeed significantly reduced renal 24-hy-
droxylase activity; however, glyoxylate also induced mild renal
failure in these animals. Consequently, the suppression of 24-
hydroxylase activity cannot be attributed to glyoxylate alone, as
uremia could also suppress the enzymatic activity of 24-hydroxy-
lase [25].
In summary, we have demonstrated that glyoxylate can inhibit
VDR-VDRE interactions in vitro. Glyoxylate also blocked calci-
triol induced expression of CAT activity in transiently transfected
JEG cells and suppressed the activity of intestinal 24-hydroxylase
in rats. Taken together, our findings suggest that glyoxylate could
inhibit VDR binding to VDRE. This compound potentially could
alter the biological action of ealcitriol in renal failure.
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